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Abstract Ductal carcinoma in situ (DCIS) is a precursor of
invasive breast carcinoma (IBC). The DCIS component is
often more extensive than the invasive component, which
affects local control. The aim of our study was to analyze
features of DCIS within different IBC subtypes, which may
contribute to the optimization of personalized approaches
for patients with IBC. Patients with IBC reported according
to the synoptic reporting module in the Netherlands
between 2009 and 2015 were included. Data extraction
included characteristics of the invasive component and, if
present, several features of the DCIS component. Resection
margin status analyses were restricted to patients under-
going breast-conserving surgery (BCS). Differences
between subtypes were tested by a Chi-square test, spear-
man’s Rho test or a one-way ANOVA test. Overall, 36.937
cases of IBC were included. About half of the IBCs
(n = 16.014; 43.4 %) were associated with DCIS.
Her2? IBC (irrespective of ER status) was associated with
a higher prevalence of adjacent DCIS, a larger extent of
DCIS and a higher rate of irradicality of the DCIS com-
ponent as compared to ER?/Her2- and triple-negative
subtypes (P\ 0.0001 for all variables). The prevalence of
DCIS in triple-negative IBC on the other hand was lowest.
In this large population-based cohort study, we showed
significant differences between the prevalence and extent
of DCIS according to IBC subtypes, which is also reflected
in the resection margin status in patients treated with BCS.
Our data provide important information regarding the
optimization of local therapy according to IBC subtypes.
Keywords Breast cancer subtypes  Ductal carcinoma
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Introduction
Invasive breast cancer (IBC) is a heterogeneous disease
which can be categorized into several histologic or intrinsic
subtypes that differ in their biological behavior and clinical
outcome [1–3]. Intrinsic subtypes are most precisely cate-
gorized based on multigene expression assays, although
each subtype has an immunohistochemical surrogate based
on ER, PR, Her2, and Ki-67 index [4–7]. Ductal carcinoma
in situ (DCIS) is seen as a nonobligate precursor of inva-
sive ductal carcinoma (IDC). In the last decades, the
detection rate of DCIS increased markedly in the age group
of 50–75 years, as a result of the increased use and
improved resolution of mammographic mass screening
[8, 9]. Synchronous DCIS and adjacent IDC show a high
degree of concordance regarding morphology and genetic
profiles [10–15]. The concordance of receptor expression
of ER, PR, and Her2 in DCIS and coexisting IDC is high,
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with 92 % for ER, 93–97 % for PR, and about 98–100 %
for Her2 [10–12].
Data regarding the process of progression of DCIS to
IBC is limited. Several studies reported frequencies of pure
DCIS subtypes based on immunohistochemical surrogates
originally described for IBC [5, 13, 14, 16]. In these pure
DCIS studies, the distribution of subtypes differs from
studies including IBC. In pure DCIS studies, frequencies of
Her2-positive subtypes are higher as compared to reported
frequencies in IBC; about 15–32 % of pure DCIS cases are
Her2 positive, while this frequency is lower in IBC, about
6–14 % [5, 13, 14, 16–18]. Reported frequencies of triple-
negative pure DCIS on the other hand are lower than
reported frequencies in IBC, 6–8 % in pure DCIS versus
11–13 % in IBC [5, 13, 14, 16, 17]. Regarding the Luminal
A and Luminal B subgroups, the reported frequencies for
pure DCIS and IBC are overlapping (38–63 % in pure
DCIS versus 38–73 % in IBC for luminal A and 7–28 % in
pure DCIS versus 5–26 % in IBC for luminal B)
[5, 13, 14, 16, 17, 19]. Based on these prevalences, a
mathematical, hypothetical model has been built, suggest-
ing different speeds of progression according to breast
cancer subtypes [20]. This model suggests that Her2? D-
CIS has the slowest progression to IBC, while triple-neg-
ative DCIS has the fastest progression.
Since the last decades, the proportion of patients
undergoing mastectomy decreased and the majority of
patients with localized DCIS are treated with breast-con-
serving surgery (BCS), followed by breast irradiation [21].
Overall, the local recurrence rate (LRR) for patients with
DCIS treated with BCS followed by breast irradiation is
about 10–17 % within the first 15 years after treatment, of
which 50 % concerns IBC [22–24]. Recent studies reported
that DCIS subtype was an independent predictor for ipsi-
lateral recurrence after treatment by breast surgery alone
(BCS or mastectomy) or breast surgery followed by breast
irradiation [25–28]. The overall LRR in patients with pure
DCIS was the highest in Her2-positive and luminal B
subgroups (10–48 % and 25–42 % recurring within
10 years of follow-up, respectively) and the lowest in the
luminal A subgroup (9–21 %) [25–27]. Regarding triple-
negative DCIS, no firm conclusion could be drawn from
the reported LRRs due to limited numbers of patients.
Nevertheless, based on LRRs per subtype, Her2-positive
DCIS seems to have an increased risk for LR after breast
surgery as compared to Her2-negative DCIS. In line with
this, the highest LRR was also observed for Her2-positive
IBC following breast surgery and irradiation (LRR of
8–21 % within 10 years of follow-up), as compared to
Luminal A and Luminal B type IBC (LRR 1–8 % and
2–10 % respectively) [29–31]. These data suggest that
adjustment of current treatment guidelines according to
breast cancer subtypes, e.g., aggressive local therapy
restricted to patients with a high LRR, could result in
reduction of complications and costs for low risk patients.
Subtyping of DCIS has the potential to study progres-
sion-related features and to identify patients at high risk for
LR. However, in daily practice, pure DCIS cases are not
routinely analyzed for ER, PR and Her2 status, which
limits the opportunity for large-scale retrospective studies.
Patients with IBC on the other hand are routinely studied
for ER, PR, and Her2 status. This provides the opportunity
to indirectly assess adjacent DCIS features, which, as
mentioned above, share receptor expression pattern in the
vast majority of cases. The aim of this study was to analyze
features of DCIS within different IBC subtypes, including
the resection margin status in patients treated with BCS,
which may contribute to the optimization of personalized
approaches for patients with IBC.
Patients and methods
Data acquisition
In the Netherlands, all pathology reports are archived in the
Dutch Pathology Registry (PALGA) [32]. Since 2009,
synoptic reporting modules for reporting several common
tumor types including breast cancer became available. In
these modules, the parameters are captured in numerous
variables instead of free text fields. This offers the unique
opportunity to analyze all reports created with the module
simultaneously.
Patient and tumor characteristics
For this study, we included all patients with IBC reported
according to the protocol module in the Netherlands
between January 1, 2009 and September 1, 2015
(n = 36.937 cases). Patients with missing ER, PR, and/or
Her2 status; pure DCIS; and patients with IBC after pre-
vious treatment (irradical resection, neoadjuvant therapy)
were excluded. Patients with bilateral IBC were included as
two cases. In case of multiple IBCs in one breast, the lar-
gest IBC was included for analysis of tumor characteristics,
except for resection margin status, which was assessed for
all tumors.
Clinicopathologic characteristics included age, type of
surgical procedure (BCS or mastectomy), tumor size
(B2 cm,[2 to B5 cm or[5 cm), histological type (ac-
cording to WHO), grade (according to the modified Bloom
and Richardson grading system) [33], ER status, PR status,
Her2 status, presence of angioinvasion, presence of DCIS,
and nodal status. ER status and PR status were defined as
positive in case more than 10 % of the cancer cells that
showed nuclear staining, irrespective of density, according
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to the Dutch Guideline for breast cancer treatment [34].
Her2 status was scored according to the international
guidelines [35]. Based on immunohistochemistry, tumors
were divided according to the surrogate definitions of
intrinsic subtypes as reported in the St Gallen International
Expert Consensus 2013 [36]. Low PR expression was
defined as B20 % [37]. However, the absence of infor-
mation regarding Ki-67 indexes in our dataset limited the
ability to differentiate between Luminal A and Luminal B
(Her2-) subtypes, so based on the available information,
our cases were subtyped according to the following 5
categories:
1. ER?/PR high/Her2-,
2. ER?/PR- or low/Her2-,
3. ER?/Her2?,
4. ER-/PR-/Her2?, and
5. ER-/PR-/Her2-.
In case DCIS was present, the following features were
documented: relation to the invasive component (restricted
to invasive component or not), diameter, nuclear grade, and
presence of microcalcifications [38]. The overall resection
margin status was reported, as well as the margin for both
the invasive component and the DCIS component as either
free, focally irradical, or more than focally irradical,
according to the Dutch Guideline for Breast Cancer
Treatment [34]. Focally irradical is defined as tumor (either
invasive or DCIS) reaching the ink in a small area
(B4 mm). In case the tumor (either invasive or DCIS)
reaches the ink in a larger area or multiple smaller areas, it
is defined as more than focally irradical. This distinction
has important clinical consequences in the Netherlands,
since patients with a focally positive resection margin of
IBC or adjacent DCIS do not undergo second surgery
(since radiation with a boost dose results in adequate local
control), while patients with a more than focally positive
resection margin undergo reexcision, according to the
Dutch Guideline for Breast Cancer Treatment 2002 [39].
However, these definitions are not applied in most other
European and North American countries [40]. Therefore, in
this study, we use the term irradicality to describe either
focally or more than focally irradical resection margins.
Statistical analysis
Differences between IBC subtypes were tested by means of
a Chi-square test (categorical variables) or a one-way
ANOVA (continuous variables). Missing values are
included in the tables but excluded in the analyses.
Furthermore, the correlation between grade of the
invasive component and the DCIS component was tested
with Chi-square. The correlation between the extent of the
DCIS component and resection margin status of the DCIS
component was tested with a spearman’s correlation
coefficient. All analyses were performed with SAS Enter-
prise Guide 7.1.
Results
Baseline characteristics
Overall, we included 36.937 consecutive cases of IBC
reported between January 1, 2009 and September 1, 2015.
The median age of our patient cohort was 62 years (range
18–100). The majority of patients (60.4 %) underwent BCS.
Table 1 provides an overview of clinicopathologic data of all
patients. About half of the IBCs (n = 16.014; 43.4 %) were
associated with DCIS, either restricted within or outside the
invasive component (45.3 and 54.7 %, respectively).
Table 2 provides details of all patients with IBC and
adjacent DCIS. Overall, there was a strong correlation
between grade of the DCIS component and grade of the
invasive component (p\0.0001, Chi-square test). Both the
extent of DCIS and DCIS extending beyond the invasive
component correlated with irradicality of the DCIS com-
ponent (spearman’s rho = 0.3, p\0.0001 and P\0.0001,
Chi-square test, respectively). The frequency of multiple
IBCs was significantly higher in IBC cases with adjacent
DCIS (10.2 %) as compared to IBC cases without adjacent
DCIS (7.4 %) (p\ 0.0001, Chi-square test).
Clinicopathologic features according to breast
cancer subtypes
Based on immunohistochemical stainings, IBCs were cat-
egorized into the following 5 categories: ER?/PR high/
Her2- (n = 21315; 57.7 %), ER?/PR- or low/Her2-
(n = 7541; 20.4 %), ER?/Her2? (n = 2806; 7.6 %),
ER-/PR-/Her2? (n = 1334; 3.6 %), or ER-/PR-/
Her2- (n = 3941; 10.7 %). Table 3 provides an overview
of patient and tumor characteristics according to different
IBC subtypes.
Overall, regarding the invasive component, the ER-/
Her2? and triple-negative subgroups showed the most
aggressive biological features. The ER?/Her2- subgroups
showed the most favorable biological features while the
ER?/Her2? subgroup showed intermediate results.
Regarding the ER?/Her2- subgroups, the presence of a
high PR expression was associated with more favorable
tumor characteristics as compared to those cases with
absence or low PR expression.
In general, patients with Her2? (irrespective of ER
status) and triple-negative IBC were younger as compared
to patients with ER?/Her2- IBC (P\ 0.0001). Besides,
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Table 1 Baseline
characteristics of all patients
with IBC (n = 36937)
Characteristic N (%)
Age at diagnosis, years, mean, median (range) Mean: 61.0
Median: 62.0 (18–100)
Type of surgery
Breast-conserving surgery 22,328 60.45
Mastectomy 14,609 39.55
Histologic tumor type
Ductal 29,630 80.22
Lobular 4703 12.73
Other 2604 7.05
Tumor size
B2 cm 24,359 65.95
[2 to B5 cm 11,117 30.10
[5 cm 1461 3.96
Tumor grade
1 8622 27.13
2 14,894 46.86
3 8266 26.01
Missing 5155 –
ER status
Positive 31,662 85.72
Negative 5275 14.28
PR status
Positive 25,400 68.77
Negative 11,487 31.10
Her2 status
Positive 4140 11.21
Negative 32,797 88.79
Multiple invasive tumors
Yes 2650 8.63
No 28,051 91.37
Missing 6236
Angioinvasion
Yes 3715 14.03
No 22,773 85.97
Missing 10,449 –
Presence of DCIS component
Yes 16,014 43.35
No 20,923 56.65
Overall resection margin status (invasive component and/or DCIS component)a
Free 18,552 83.09
Focally irradical 2286 10.24
More than focally irradical 1490 6.67
Resection margin status of invasive component onlya
Free 19,755 88.48
Focally irradical 1621 7.26
More than focally irradical 952 4.26
Nodal status
Negative 11,428 60.22
Positive 7550 39.78
Missing 17,959 –
a Analysis restricted to patients with BCS (n = 22328)
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median tumor size of these subtypes was larger (P\
0.0001), which was in line with the higher proportion of
patients undergoing a mastectomy (P\ 0.0001). Histo-
logically, these tumors were more often of ductal type (p\
0.0001) and of higher grade (P\ 0.0001). The frequency
of angioinvasion and nodal involvement was highest in the
ER-/Her2? subgroup (P\ 0.0001).
There was a strong correlation between the presence of
DCIS and breast cancer subtype (P\ 0.0001). Table 4
provides an overview of all DCIS characteristics according
to different subtypes of IBC. DCIS was most often present
adjacent to IBCs with overexpression of Her2 (irrespective
of ER status) with a frequency of 59.1 % in the ER?/
Her2? subgroup and 57.4 % in the ER-/Her2? subgroup.
The frequency of a DCIS component was lowest in the
triple-negative subgroup (34.1 %).
Besides a higher prevalence of DCIS in the
Her2? groups, DCIS was more often located outside the
invasive component and the DCIS component was more
extensive (P\ 0.0001 for all variables). DCIS-associated
microcalcifications were most often seen adjacent to
Her2? IBC, while the frequency was lowest in the triple-
negative group (p\ 0.0001).
Analysis of resection margin status was restricted to
patients treated with BCS. Overall, the frequency of
irradicality (of either the invasive or the DCIS component)
was highest in the Her2? subgroups and lowest in the
triple-negative subgroup (P\ 0.0001). Analysis of irradi-
cality of the invasive component separately showed the
highest frequency of irradicality in the ER?/Her2- sub-
groups and the lowest in the triple-negative subgroup (P\
0.0001). Analysis of irradicality of the DCIS component
however showed another distribution as compared to the
irradicality of the invasive component; the frequency of
irradicality of the DCIS component was highest in the
Her2? subgroups (P\ 0.0001).
Discussion
Our national registration system for pathology reporting
provided a unique opportunity for this large-scale popula-
tion-wide cohort study describing the presence and extent
of DCIS according to breast cancer subtypes, in relation to
other clinicopathologic features.
In our study, we showed substantial differences between
immunohistochemical breast cancer subtypes regarding
age, type of surgery, histology, tumor grade, and tumor
size, which is consistent with literature [41, 42]. Briefly,
Her2? and triple-negative tumors are associated with
younger age, larger size, and higher grade compared to
luminal subtypes. However, on the other side of the spec-
trum, ER?/Her2- IBC showed the most favorable tumor
Table 2 DCIS characteristics
of all patients with IBC and
adjacent DCIS (n = 16014)
Characteristic N (%)
DCIS grade
1 2598 16.33
2 7896 49.64
3 5414 34.03
Missing 106 –
DCIS restricted to invasive component
Yes 4452 45.29
No 5377 54.71
Missing 6185 –
Diameter of DCIS, cm, mean, median (range) Mean: 2.08
Median: 1.50 (0–20)
–
Presence of DCIS-associated microcalcifications
Yes 4400 49.97
No 4406 50.03
Missing 7208 –
Resection margin status of DCIS component onlya
Free 8323 83.67
Focally irradical 1168 11.74
More than focally irradical 456 4.58
Missing 34
a Analysis restricted to patients with BCS (n = 9981)
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characteristics, especially in the case of a high PR
expression. This is in line with recent work of Prat et al. in
which they concluded that the addition of a PR expression
of more than 20 % adds prognostic value within the current
immunohistochemical-based luminal A definition by
improving the identification of IBCs with a good prognosis
Table 3 Clinicopathologic characteristics according to different subtypes of IBC (n = 36937)
Characteristic ER?, PR high,
Her2-
(n = 21315)
ER?, PR-
or low
Her2-
(n = 7541)
ER?, Any
PR,
Her2?
(n = 2806)
ER-, PR-,
Her2?
(n = 1334)
ER-, PR-,
Her2-
(n = 3941)
P-value
Age at diagnosis, years, mean, median and range Mean: 61.1
Median: 62
Range: 18–99
Mean: 63.4
Median: 64
Range:
21–97
Mean: 57.6
Median: 57
Range:
19–100
Mean: 59.3
Median: 59
Range:
24–97
Mean: 59.0;
Median: 59
Range:
22–98
\0.0001
Type of surgery, no (%) \0.0001
Breast-conserving surgery 13,507 63.37 4476 59.36 1514 53.96 599 44.90 2232 56.64
Mastectomy 7808 36.63 3065 40.64 1292 46.04 735 55.10 1709 43.36
Tumor type, no (%) \0.0001
Ductal 16,695 78.33 5753 76.29 2548 90.81 1255 94.08 3379 85.74
Lobular 3130 14.68 1319 17.49 147 5.24 20 1.50 87 2.21
Other 1490 6.99 469 6.22 111 3.96 59 4.42 475 12.05
Tumor size, no (%) \0.0001
B2 cm 14,849 69.66 4931 65.39 1719 61.26 729 54.65 2131 54.07
[2 to B5 cm 5771 27.07 2267 30.06 964 34.35 528 39.58 1587 40.27
[5 cm 695 3.26 343 4.55 123 4.38 77 5.77 223 5.66
Tumor grade, no (%) \0.0001
1 6513 35.17 1786 27.41 203 8.63 29 2.62 91 2.77
2 9559 51.62 3379 51.86 1018 43.28 273 24.66 665 20.21
3 2445 13.20 1351 20.73 1131 48.09 805 72.72 2534 77.02
Missing 2798 – 1025 – 454 – 227 – 651 –
Multiple invasive tumors, no (%) \0.0001
Yes 1624 9.02 510 8.25 216 9.45 106 9.97 194 5.97
No 16,296 90.94 5671 91.75 2070 90.55 957 90.03 3057 94.03
Missing 3395 – 1360 – 520 – 271 – 690 –
Angioinvasion, no (%) \0.0001
Yes 1734 11.20 727 13.46 427 21.72 267 29.28 560 20.52
No 13,747 88.80 4673 86.54 1539 78.28 645 70.72 2169 79.48
Missing 5834 – 2141 – 840 – 422 – 1212 –
Overall resection margin status (invasive and/or DCIS component)a \0.0001
Free 11,243 83.24 3676 82.13 1205 79.59 459 76.63 1969 88.22
Focally irradical 1366 10.11 492 10.99 178 11.76 92 15.36 158 7.08
More than focally irradical 898 6.65 308 6.88 131 8.65 48 8.01 105 4.70
Resection margin status of invasive componenta, no (%) \0.0001
Free 11,879 87.95 3910 87.35 1344 88.77 540 90.15 2082 93.28
Focally irradical 1028 7.61 356 7.95 112 7.40 41 6.84 84 3.76
More than focally irradical 600 4.44 210 4.69 58 3.83 18 3.01 66 2.96
Nodal status, no (%) \0.0001
Negative 6717 62.17 2293 59.19 774 53.20 359 47.61 1285 61.45
Positive 4087 37.83 1581 40.81 681 46.80 395 52.39 806 38.55
Missing 10,511 – 3667 – 1351 – 580 – 1850 –
a Analysis restricted to patients with BCS (n = 22328)
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[37]. The ER?/Her2? group seems to be an intermediate
subgroup.
Regarding DCIS, we showed that Her2? IBC is asso-
ciated with a higher prevalence of adjacent DCIS and a
larger extent of DCIS as compared to other IBC subtypes.
In line with this, we reported a relatively high rate of
irradicality of the DCIS component in Her2? IBC. These
findings are consistent with previous studies reporting a
relatively high rate of Her2 positivity in pure DCIS cases,
presence of extensive DCIS adjacent to Her2? IBC, and a
high LRR after BCS for Her2? IBC [13, 29, 30, 42, 43].
Since the risk of an irradical resection is higher for IBCs
that are associated with an extensive DCIS component as
compared to those with a limited in situ component
[41, 44], it seems likely that the DCIS component adjacent
to Her2? IBC is responsible for the high LRR. Therefore,
preoperative knowledge regarding the extent of DCIS
according to breast cancer subtypes may result in adjust-
ment of local therapy and consequently local control. This
may reduce undertreatment in those patients with a large
DCIS component, including fewer secondary surgeries and
local recurrences. On the other hand, it may result in less
overtreatment in those patients with a low prevalence and/
or limited extent of DCIS, e.g., by reduction of excision
volume which affects cosmetic outcome. In recent years,
there is an increased number of pathology laboratories
performing the ER, PR, and Her2 status on preoperative
needle biopsies on a routine basis, mainly as a result of the
increased use of neoadjuvant treatment, which provides a
better understanding of tumor growth patterns preopera-
tively. The presence of DCIS-associated microcalcifica-
tions adjacent to the majority of Her2? IBCs, as shown in
this study, may provide important preoperative information
regarding imaging by mammography. Besides, since the
DCIS component adjacent to Her2? IBCs is mainly of
high grade, a preoperative MRI could be beneficial for
these patients, particularly for those without microcalcifi-
cations, since this imaging technique is considered to be
the most sensitive modality in detecting the presence and
extent of intermediate- and high-grade DCIS [45, 46].
Table 4 DCIS characteristics according to different subtypes of IBC (n = 16014)
Characteristic ER?, PR high,
Her2-
(n = 21315)
ER?, PR- or
low
Her2-
(n = 7541)
ER?, Any
PR,
Her2?
(n = 2806)
ER-, PR-,
Her2?
(n = 1334)
ER-, PR-,
Her2-
(n = 3941)
P-value
Presence of DCIS, no (%) \0.0001
Yes 9168 43.01 3078 40.82 1658 59.09 766 57.42 1344 34.10
No 12,147 56.99 4463 59.18 1148 40.91 568 42.58 2597 65.90
DCIS grade, no (%) \0.0001
1 1983 21.77 512 16.72 61 3.70 4 0.53 38 2.86
2 5310 58.32 1613 52.66 572 34.73 106 13.93 294 21.11
3 1813 19.91 938 30.62 1014 61.57 651 85.55 998 75.04
Missing 61 – 15 – 11 – 5 – 14 –
Presence of DCIS-associated microcalcifications, no (%) \0.0001
Yes 2464 48.21 876 52.02 512 59.26 240 60.91 308 40.90
No 2647 51.79 808 47.98 352 40.74 154 39.09 445 59.10
Missing 4057 – 1394 – 794 – 372 – 591 –
DCIS restricted to invasive component, no (%) \0.0001
Yes 2774 48.52 823 43.82 383 39.24 127 29.13 345 41.97
No 2943 51.48 1055 56.18 593 60.76 309 70.87 477 58.03
Missing 3451 – 1200 – 682 – 330 – 522 –
Diameter of DCIS, cm, mean, median and range Mean: 1.9;
Median: 1.4
Range: 0–20
Mean: 1.9;
Median: 1.4
Range:
0–19
Mean: 2.6;
Median: 2.0
Range:
0–20
Mean: 3.2;
Median:
2.3 Range:
0–20
Mean: 2.1;
Median: 1.5
Range:
0–15
\0.0001
Resection margin status of DCIS componenta
Free 5103 85.33 1622 83.44 707 78.82 251 71.10 640 82.79 \0.0001
Focally irradical 640 10.70 245 12.60 127 14.16 73 20.68 83 10.74
More than focally irradical 237 3.96 77 3.96 63 7.02 29 8.22 50 6.47
Missing 22 – 5 – 2 – 0 – 5 –
a Analysis restricted to patients with BCS and presence of DCIS
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According to our knowledge, our study includes the
largest series of patients ever published regarding the
presence and extent of DCIS adjacent to breast cancer
subtypes, thanks to our national protocolled registration of
breast cancer pathology reports. However, our study also
has several weaknesses including the missing data
regarding receptor expression of the DCIS component.
However, since several studies reported a very high con-
cordance (90–100 %) of ER, PR, and Her2 expression
between DCIS and adjacent IBC, it is highly unlikely that
this has affected our results. The second limitation is the
lack of information regarding proliferation, because Ki-67
is not routinely performed in our pathology laboratories.
This limited an accurate categorization of luminal A versus
luminal B subtypes, which is partly based on a low versus a
high Ki-67 index. A third limitation of our study is the lack
of clinical follow-up regarding local control. In this study,
we used data from 2009 (in this year we started registering
according to standard pathology protocols) until 2015,
resulting in inadequate follow-up time.
In conclusion, in this large population-based cohort
study, we showed significant differences between the
prevalence and extent of DCIS according to breast cancer
subtypes. Her2? IBC was associated with the highest
prevalence and extent of DCIS, while on the other side of
the spectrum, triple-negative IBC had the lowest preva-
lence of DCIS of all IBC subtypes. Since the extent of
DCIS was also reflected in the resection margin status in
patients treated with BCS, these data provide important
information regarding the optimization of local therapy.
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